Design Therapeutics, Inc. Common Stock

Design Therapeutics announced positive Phase 1/2 data from its RESTORE-FA trial showing DT-216P2 demonstrated dose-dependent clinical improvements in Friedreich ataxia patients after four weeks of treatment, including improvements in mFARS scores, upright stability, and fatigue. The drug showed comprehensive biomarker activity with 65% increase i...

Design Therapeutics announced it will present Phase 1/2 RESTORE-FA trial data for DT-216P2, its experimental treatment for Friedreich's ataxia, on May 18, 2026. The company is advancing multiple clinical-stage programs using its GeneTAC gene-targeted chimera platform, with trials ongoing for corneal dystrophy and myotonic dystrophy treatments, an...

Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ...

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider ...